Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes
- PMID: 20584360
- DOI: 10.1017/S0266462310000309
Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes
Abstract
Background: The way in which a health technology is used in any particular health system depends on the decisions and actions of a variety of stakeholders, the local culture, and context. In 2009, the HTAi Policy Forum considered how health technology assessment (HTA) could be improved to optimize the use of technologies (in terms of uptake, change in use, or disinvestment) in such complex systems.
Methods: In scoping, it was agreed to focus on initiatives to implement evidence-based guidance and monitoring activities. A review identified systematic reviews of implementation initiatives and monitoring activities. A two-day deliberative workshop was held to discuss key papers, members' experiences, and collectively address key questions. This consensus paper was developed by email and finalized at a postworkshop meeting.
Results: Evidence suggests that the impact and use of HTA could be increased by ensuring timely delivery of relevant reports to clearly determined policy receptor (decision-making) points. To achieve this, the breadth of assessment, implementation initiatives such as incentives and targeted, intelligent dissemination of HTA result, needs to be considered. HTA stakeholders undertake a variety of monitoring activities, which could inform optimal use of a technology. However, the quality of these data varies and is often not submitted to an HTA.
Conclusions: Monitoring data should be sufficiently robust so that they can be used in HTA to inform optimal use of technology. Evidence-based implementation initiatives should be developed for HTA, to better inform decision makers at all levels in a health system about the optimal use of technology.
Similar articles
-
Using health technology assessment to support optimal use of technologies in current practice: the challenge of "disinvestment".Int J Technol Assess Health Care. 2012 Jul;28(3):203-10. doi: 10.1017/S0266462312000372. Epub 2012 Jul 16. Int J Technol Assess Health Care. 2012. PMID: 22792877
-
Health technology assessment: research trends and future priorities in Europe.J Health Serv Res Policy. 2011 Jul;16 Suppl 2:6-15. doi: 10.1258/jhsrp.2011.011050. J Health Serv Res Policy. 2011. PMID: 21737525
-
[Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].Acta Med Croatica. 2010 Dec;64(5):425-34. Acta Med Croatica. 2010. PMID: 21692267 Croatian.
-
Developing Health Technology Assessment to address health care system needs.Health Policy. 2010 Mar;94(3):196-202. doi: 10.1016/j.healthpol.2009.10.002. Epub 2009 Nov 3. Health Policy. 2010. PMID: 19889471 Review.
-
Role of health technology assessment in shaping the benefits package in The Netherlands.Expert Rev Pharmacoecon Outcomes Res. 2009 Feb;9(1):85-94. doi: 10.1586/14737167.9.1.85. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19371181 Review.
Cited by
-
Exploring the landscape of health technology assessment in Iran: perspectives from stakeholders on needs, demand and supply.Health Res Policy Syst. 2024 Jan 15;22(1):11. doi: 10.1186/s12961-023-01097-0. Health Res Policy Syst. 2024. PMID: 38225573 Free PMC article. Review.
-
How health technology reassessment can support disinvestment in China's national drug reimbursement list.BMJ. 2023 Jun 15;381:e068917. doi: 10.1136/bmj-2021-068917. BMJ. 2023. PMID: 37321624 Free PMC article.
-
[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0].J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec. J Prev Med Hyg. 2023. PMID: 37034835 Free PMC article. Italian. No abstract available.
-
Improving access to SLE therapies in low and middle-income countries.Rheumatology (Oxford). 2023 Mar 29;62(Suppl 1):i30-i35. doi: 10.1093/rheumatology/keac530. Rheumatology (Oxford). 2023. PMID: 36987603 Free PMC article. Review.
-
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.NPJ Precis Oncol. 2022 Oct 25;6(1):76. doi: 10.1038/s41698-022-00316-1. NPJ Precis Oncol. 2022. PMID: 36284134 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources

